Reports from other IL-17 inhibitors such as secukinumab have reported 3 cases of UC, 3 cases of CD and 2 cases of IBD unclassified (EAIRs 0.08, 0.08, and 0.05); 7 of these represented new onset cases [25]. Here, IL17A is linked to inflammatory bowel disease.